CoChat
Sign Up
Cited by 11

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Omalizumab is effective for a patient with pollen-food allergy syndrome who experienced intractable lip edema

Sakamoto, Daiki, Hamada, Satoko, Kobayashi, Yoshiki, Shimono, Masami, Shimamura, Akihiro, Kanda, Akira, Asako, Mikiya, Iwai, Hiroshi·2023·Auris Nasus Larynx
DOI 10.1016/j.anl.2022.12.001
Open this paper in CoChat — free account

Abstract

Pollen-food allergy syndrome (PFAS) is an immunoglobulin E (IgE)-mediated allergic reaction caused when patients with pollen allergy ingest food having cross-reactivity with pollen. To date, no effective treatment method for this has been established. Here we report the case of a patient with PFAS who experienced lip edema, causing difficulties in treatment. This report describes the case of a 12-year-old boy with perennial allergic rhinitis since the age of 8 years. After ingesting fresh fruits and raw vegetables at the age of 11 years, he started to experience lip edema repeatedly. Thus, the patient was referred to our department. Based on the results of serum antigen-specific IgE, prick-to-prick, and allergen component tests, he was diagnosed with PFAS. He has been instructed to avoid causative food. Furthermore, the treatment using an antihistamine and antileukotriene receptor antagonist was initiated for pollen allergy. Sublingual immunotherapy (SLIT) for Japanese cedar pollen was initiated because the patient experienced severe nasal allergy symptoms during the dispersal season of this pollen. These treatments alleviated the nasal symptoms; however, the lip edema persisted. Omalizumab administration improved the lip edema. The combination of SLIT and omalizumab may be an effective treatment option for patients with PFAS.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.anl.2022.12.001

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 19

  1. Amlot, 1987, Oral allergy syndrome(OAS): symptoms of IgE-mediated hypersensitivity to foods, Clin Allergy, 17, 33, 10.1111/j.1365-2222.1987.tb02317.x · DOI
  2. Yagami, 2019, New findings, pathophysiology, and antigen analysis in pollen-food allergy syndrome, Curr Opin Allergy Clin Immnol, 19, 218, 10.1097/ACI.0000000000000533 · DOI
  3. Ebisawa, 2017, Japanese guidelines for food allergy 2017, Allergol Int, 66, 248, 10.1016/j.alit.2017.02.001 · DOI
  4. Furci, 2021, Plant Food Allergy Improvement after Grass Pollen Subligual Immunotherapy: A Case Series, Pathogens, 10, 1412, 10.3390/pathogens10111412 · DOI · Paper page
  5. Okubo, 2020, Japanese guidelines for allergic rhinitis 2020, Allegol Int, 69, 331, 10.1016/j.alit.2020.04.001 · DOI
  6. Asero, 2017, Disappearance of severe oral allergy syndrome following omalizumab treatment, Eur Ann Allergy Clin Immunol, 49, 143
  7. Griffiths, 2017, Comparison of the Performance of Skin Prick, ImmnoCAP, and ISAC Tests in the Diagnosis of Patients with Allergy, Int Arch Allergy Immunol, 172, 215, 10.1159/000464326 · DOI
  8. Tsumagari, 2018, Evaluation of the effectiveness of subcutaneous immunotherapy using birch pollen extract for pollen-food allergy syndrome, Arerugi, 67, 211
  9. Hansen, 2004, Food allergy to apple and specific immunotherapy with birch pollen, Mol Nutr Food Res, 48, 441, 10.1002/mnfr.200400037 · DOI
  10. Kinaciyan, 2007, Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1, J Allergy Clin Immunol, 119, 937, 10.1016/j.jaci.2006.11.010 · DOI
  11. Kinaciyan, 2018, Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy, J Allergy Clin Immunol, 141, 1002, 10.1016/j.jaci.2017.07.036 · DOI
  12. Sanches Acosta, 2020, IgE-blocking antibodies following SLIT with recombinant Mal d 1 accord with improved apple allergy, J Allergy Clin Immunol, 146, 894, 10.1016/j.jaci.2020.03.015 · DOI
  13. Dantzer, 2018, The use of omalizumab in allergen immunotherapy, Clin Exp Allergy, 48, 232, 10.1111/cea.13084 · DOI
  14. Wood, 2016, A randomized, double blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy, J Allergy Clin Immunol, 137, 1103, 10.1016/j.jaci.2015.10.005 · DOI
  15. MacGinnitie, 2017, Omalizumab facilitates rapid oral desensitization for peanut allergy, J Allergy Clin Immunol, 139, 873, 10.1016/j.jaci.2016.08.010 · DOI
  16. Sindher, 2022, Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study, Allergy, 77, 1873, 10.1111/all.15217 · DOI
  17. Liu, 2022, Efficacy and safety of omalizumab for the treatment of severe or poorly controlled allergic diseases in children: A systematic review and meta-analysis, Front Pediatr, 10
  18. Just, 2021, Omalizumab effectiveness in severe allergic asthma with multiple allergic comorbidities: A post-hoc analysis of the STELLAIR Study, J Asthma Allergy, 14, 1129, 10.2147/JAA.S310888 · DOI
  19. Wensing, 2002, IgE to Bet v 1 and profilin: cross-reactivity patterns and clinical relevance, J Allergy Clin Immunol, 110, 435, 10.1067/mai.2002.126380 · DOI

Cited by

Sorted by citations

See all 11

Metadata

Authors
Sakamoto, D., Hamada, S., Kobayashi, Y., Shimono, M., Shimamura, A., Kanda, A., Asako, M., & Iwai, H.
ORCID
Kobayashi, Yoshiki
Venue
Auris Nasus Larynx
Publisher
Elsevier BV
Published
2023-10
Volume
50
Issue
5
Pages
805-810
ISSN
0385-8146
DOI
10.1016/j.anl.2022.12.001
Cited by
11
References
3
Language
en
Licence
Funders
Kansai Medical University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review